Sanjay Nilapwar works as Purification Process Scientist in Novel Molecules group of Medimmune, Gaithersburg and is also part of platform ADC CMC development team.
In current position, he looks after transitioning of ADC/mAb molecules from candidate drug to development and manufacturing stage, encompassing cycle 1 and 2 process and purification development, technology transfer and related CMC aspects including filing IND/IMPDs.
In 2013 Nilapwar started working for Spirogen, prior to its takeover by Medimmune, where he worked on development of site-specific and stochastic PBD based conjugation at research scale, stability and analytical assay development and was instrumental in setting up large scale ADC purification lab within Medimmune.
He started working on protein conjugates at Piramal Lifescience by conjugating a range of therapeutic drugs including cytotoxics and radiolabeled chelates to therapeutic mAbs for Targeted therapies.
Nilapwar has more than 12 years of experience in protein/conjugates purification development and has published 9 papers and written couple of book chapters. He regularly speaks at ADC conferences and chairs conference session.
Nilapwar has earned his Ph.D in Molecular Biology and Biophysics from UCL, London and M. Pharm in Pharmaceutical Chemistry from Mumbai University.
Last Editorial Review: August 31, 2017
Copyright © 2016 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.